Spencer Net Income From Continuing Ops from 2010 to 2026

SPPH Stock  USD 0.0001  0.00  0.00%   
Spencer Pharmaceutical's Net Loss is decreasing with slightly volatile movements from year to year. Net Loss is estimated to finish at about -806.4 K this year. For the period between 2010 and 2026, Spencer Pharmaceutical, Net Loss quarterly trend regression had mean deviation of  156,589 and range of 1.4 M. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-848.9 K
Current Value
-806.4 K
Quarterly Volatility
334.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Spencer Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spencer Pharmaceutical's main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 0.0 or Selling General Administrative of 754.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0. Spencer financial statements analysis is a perfect complement when working with Spencer Pharmaceutical Valuation or Volatility modules.
  
Build AI portfolio with Spencer Stock
Check out the analysis of Spencer Pharmaceutical Correlation against competitors.
For more detail on how to invest in Spencer Stock please use our How to Invest in Spencer Pharmaceutical guide.
The Net Income From Continuing Ops trend for Spencer Pharmaceutical offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Spencer Pharmaceutical is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Spencer Pharmaceutical's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Spencer Pharmaceutical over the last few years. It is Spencer Pharmaceutical's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Spencer Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Spencer Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(848,174)
Geometric Mean888,162
Coefficient Of Variation(39.44)
Mean Deviation156,589
Median(943,196)
Standard Deviation334,511
Sample Variance111.9B
Range1.4M
R-Value(0.34)
Mean Square Error105.2B
R-Squared0.12
Significance0.18
Slope(22,843)
Total Sum of Squares1.8T

Spencer Net Income From Continuing Ops History

2026-806.4 K
2025-848.9 K
2011-943.2 K
2010441.1 K

About Spencer Pharmaceutical Financial Statements

Investors use fundamental indicators, such as Spencer Pharmaceutical's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Spencer Pharmaceutical's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Loss-848.9 K-806.4 K

Currently Active Assets on Macroaxis

When determining whether Spencer Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spencer Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spencer Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spencer Pharmaceutical Stock:
Check out the analysis of Spencer Pharmaceutical Correlation against competitors.
For more detail on how to invest in Spencer Stock please use our How to Invest in Spencer Pharmaceutical guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is there potential for Biotechnology market expansion? Will Spencer introduce new products? Factors like these will boost the valuation of Spencer Pharmaceutical. If investors know Spencer will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Spencer Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets
(1.42)
The market value of Spencer Pharmaceutical is measured differently than its book value, which is the value of Spencer that is recorded on the company's balance sheet. Investors also form their own opinion of Spencer Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Spencer Pharmaceutical's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Spencer Pharmaceutical's market value can be influenced by many factors that don't directly affect Spencer Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spencer Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Spencer Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Spencer Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.